NO_LONGER_AVAILABLENCT03941782
Compassionate Use of BYL 719 Alpelisib
Studying Isolated rare lymphatic malformation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- New Mexico Cancer Research Alliance
- Principal Investigator
- Ian Rabinowitz, MDUniversity of New Mexico Cancer Center
- Intervention
- Alpelisib(drug)
- Eligibility
- 18 years · All sexes
Study locations (1)
- University of New Mexico - Cancer Center, Albuquerque, New Mexico, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03941782 on ClinicalTrials.gov